Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited “significant” upside from the current valuation for the ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $284.00. The company’s shares closed yesterday at $264.89.

Perform material- and labor-effective extrusion with Thermo Scientific™ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...

The mouse on the right with four times the normal muscle mass is placed with a normal mouse. Handout via REUTERS About a dozen drugmakers are developing new weight-loss treatments aimed at ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The stakes are clear. Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 billion by streamlining the resource- and time ...

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 96,784.07 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

قال مسؤول كبير في قطاع البيض بتركيا يوم الأربعاء إن البلاد بدأت تصدير نحو 15 ألف طن من البيض إلى الولايات ...

Sanofi S.A. Part Cert 0.02% €8.03M ...